Casali P, Licitra L, Tondini C, de Braud F, Bruzzi P, Costa A, Cavalli F
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
Ann Oncol. 1999 Jul;10(7):769-73. doi: 10.1023/a:1008318029326.
START ('State-of-the-Art Oncology in Europe'), a freely available resource on the Internet, is a European 'information base' of current clinical approaches to human tumours. Its aim is to help clinical oncologists make appropriate clinical decisions by providing them with updated information reflecting state-of-the-art cancer treatment as perceived by the European oncology community. It is based upon contributions from authors and internal reviewers from all over Europe as selected by START's editorial board under the supervision of an advisory board and a scientific committee. Close collaborations with the main European cancer societies are ongoing. An external feedback process augments the mechanisms for rendering START a truly European instrument. START is concerned with evidence-based cancer medicine, and the main clinical options are thus codified and their bases indicated in accord with a scale worked out from the perspective of clinical decision-making. Therapeutic options may be 'standard', 'investigational', or 'suitable for individual clinical use' (within the context of a decision made jointly by the patient and the physician). The goal of instruments such as START is to improve the quality of patient care. In addition, START hopes to make contributions to the methodology by which medical research is transformed into clinical decisions.
“欧洲肿瘤学前沿”（START）是互联网上一项免费资源，是关于人类肿瘤当前临床治疗方法的欧洲“信息库”。其目的是通过为临床肿瘤学家提供反映欧洲肿瘤学界所认为的最新癌症治疗方法的最新信息，帮助他们做出恰当的临床决策。它基于由START编辑委员会在顾问委员会和科学委员会监督下挑选的来自欧洲各地的作者和内部评审人员的贡献。目前正在与主要的欧洲癌症协会开展密切合作。一个外部反馈过程增强了使START成为真正欧洲工具的机制。START关注循证癌症医学，因此主要临床选项被编纂整理，并根据从临床决策角度制定的一个量表指出其依据。治疗选项可能是“标准的”、“试验性的”或“适合个体临床使用”（在患者和医生共同做出的决策背景下）。诸如START这样的工具的目标是提高患者护理质量。此外，START希望对将医学研究转化为临床决策的方法做出贡献。
